DNA vaccines |
Chemically stable and cost effective; easy and safe to scale up; can induce both humoral and cellular immune responses and are capable of mediating long-term protection |
Have the potential of integrating the exogenous gene into the host genome, leading to induction of host autoimmunity |
[17,18,19,20,21,22,25] |
Subunit vaccines |
Rapid, stable, and consistent production |
Normally need multiple doses with appropriate adjuvants |
[26,27,28,29,30,31] |
Live-attenuated vaccines |
Single dose could induce high immune responses, rapid induction of durable immunity |
Safety problems and need cold-chain storage facilities |
[24,34,35,36,37] |
Virus-vector-based vaccines |
Single dose could induce higher and faster immune responses with lasting protection |
Pre-existing immunity problem |
[39,41,42,43,44,45,48,49] |
Inactivated vaccines |
Easy production and storage; convenient to make multivalent vaccines |
Safety problems; need multiple injections; unable to deal with mutant viruses |
[59,60,61,62,63,64] |
VLP-based vaccines |
Noninfectious and could induce robust antibodies; multiple choices of expression systems |
Application for clinical use needs further studies |
[69,70,71] |
mRNA-based vaccines |
Rapid and flexible production; could induce potent humoral and cellular immune responses |
Need cold-chain storage facilities; new technology, lack of historical accumulation |
[72,73,74] |